Glympse Bio
Diagnostics company developing synthetic biomarkers called Glympse Sensors that detect disease activity and treatment response through non-invasive urine tests, transforming disease monitoring.
Notes
Glympse Bio is developing a novel approach to disease detection and monitoring using synthetic biomarkers. Unlike traditional biomarkers that measure naturally occurring substances, Glympse Sensors are engineered nanoparticles that detect disease-specific enzymatic activity in the body and release reporter molecules that can be measured in urine.
The platform enables non-invasive, real-time monitoring of disease activity, potentially replacing invasive procedures like liver biopsies. The company's initial focus is on liver diseases including non-alcoholic steatohepatitis (NASH) and liver fibrosis, conditions where current diagnostic options are limited.
Glympse Bio has raised significant venture capital and established partnerships with pharmaceutical companies interested in better endpoints for clinical trials.
Team
- Caroline Loew, Ph.D. - CEO
- LinkedIn: linkedin.com/in/carolineloew
- Sangeeta Bhatia, M.D., Ph.D. - Co-founder (MIT Professor, biomedical engineering pioneer)
- Experienced team in diagnostics and drug development
Additional Research Findings
- Founded in 2015, based in Cambridge, Massachusetts
- Portfolio company of Polaris Partners
- Synthetic biomarkers detect disease activity
- Non-invasive urine-based tests
- Initial focus on liver diseases (NASH, fibrosis)
- Could replace liver biopsies
- Partnerships with pharmaceutical companies
- Technology based on MIT research from Bhatia lab
- Machine learning for biomarker signal analysis
- Raised over $80 million in venture funding
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Polaris Partners | US | biotech-focused | - | 33 |